FDAnews Drug Daily Bulletin

FDA Will Not Require a REMS in Connection With Corcept’s Proposed Distribution of Korlym for Cushing’s Syndrome

Dec. 16, 2011
A A
Corcept Therapeutics announced it has been advised by the FDA that no Risk Evaluation and Mitigation Strategy will be required in connection with Corcept’s proposed distribution of its lead product candidate, mifepristone, to which Corcept has given the brand name Korlym.
MarketWatch